Protocol Ledger

NCT06783114 · Phase II/III · RECRUITING

A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults

Interventional Phase II/III clinical trial protocol NCT06783114 sponsored by Chongqing Claruvis Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-14 Enrollment: 254 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06783114
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)254 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06783114
Protocol FieldVerified Registry Value
NCT IdentifierNCT06783114
Consolidated Lead SponsorChongqing Claruvis Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment254 participants (ESTIMATED)
Registered Start Date2024-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI